Skip to main content

Peer Review reports

From: Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

Original Submission
12 Jul 2022 Submitted Original manuscript
29 Jul 2022 Reviewed Reviewer Report
3 Aug 2022 Reviewed Reviewer Report
12 Sep 2022 Author responded Author comments - Puyuan Xing
Resubmission - Version 2
12 Sep 2022 Submitted Manuscript version 2
17 Sep 2022 Reviewed Reviewer Report
17 Oct 2022 Reviewed Reviewer Report
29 Oct 2022 Author responded Author comments - Puyuan Xing
Resubmission - Version 3
29 Oct 2022 Submitted Manuscript version 3
Publishing
31 Oct 2022 Editorially accepted
23 Nov 2022 Article published 10.1186/s12916-022-02646-0

You can find further information about peer review here.

Back to article page